Idiopathic Pulmonary Fibrosis

March 23, 2017March 23, 2017

New Research Reveals How IPF Treatments Ofev and Esbriet Work

Researchers from Germany have identified how Ofev (nintedanib) and Esbriet (pirfenidone) work — two FDA-approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF). The study, titled “A Novel Antifibrotic Mechanism ... Read more

March 21, 2017March 21, 2017

New ‘Pulmonary Fibrosis Information Guide’ Released by PF Foundation

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) recently released its updated “Pulmonary Fibrosis Information Guide,” a resource to provide patients and families with updated information about pulmonary fibrosis (PF), treatment options, and methods of ... Read more

March 16, 2017March 16, 2017

Galecto’s TD139 Shows Promise in IPF Patients, Clinical Trial Shows

Idiopathic Pulmonary Fibrosis, News

Galecto Biotech has completed a Phase 1b/2a clinical trial that indicated its inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients. TD139 is an inhibitor of galectin-3, ... Read more

March 14, 2017March 14, 2017

Synairgen Reports Positive Data on Potential IPF Treatment

Idiopathic Pulmonary Fibrosis, News

Synairgen recently reported positive data from its ongoing work in partnership with Pharmaxis to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a new treatment for idiopathic pulmonary fibrosis (IPF). Synairgen is ... Read more

March 8, 2017March 8, 2017

Broadway Stars Belt Out Songs to Raise Record $250,000 to Fight Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

The 7th Annual Pulmonary Fibrosis Foundation benefit Broadway Belts for PFF! raised a record-breaking $250,000 – a 35 percent increase over last year – to support its work with the pulmonary fibrosis ... Read more

March 7, 2017March 7, 2017

Treatment Seen to Lessen Fibrotic Scarring That Causes Lung Transplants to Fail

Bronchiolitis, COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

Treatment may be able prevent the progressive accumulation of scar tissue (fibrosis) in newly transplanted lungs that eventually cause those organs to fail, researchers at the University of Michigan report. The study, “Autocrine lysophosphatidic ... Read more

March 6, 2017March 6, 2017

Global IPF Survey Finds Two-thirds of Patients Involved in Treatment Decisions

Idiopathic Pulmonary Fibrosis, News

Results from a new global survey of 152 people living with idiopathic pulmonary fibrosis (IPF) showed that while a majority of these patients have been involved in decisions regarding their ... Read more

March 3, 2017March 3, 2017

Study Identifies New Molecular Treatment Candidate for IPF

Idiopathic Pulmonary Fibrosis, News

Researchers have found that the activity of a protein, called heat shock protein 90 (Hsp90), is elevated in lung cells of patients with idiopathic pulmonary fibrosis (IPF). They also identified ... Read more

February 28, 2017February 28, 2017

Phase 2 Trial Results Show Promise for ProMetic’s IPF Therapy Candidate

Idiopathic Pulmonary Fibrosis, News

The completed Phase 2 clinical study evaluating ProMetic’s PBI-4050 in people with idiopathic pulmonary fibrosis (IPF) demonstrated positive trial results of the drug’s effectiveness and tolerability as a monotherapy and ... Read more

February 3, 2017February 3, 2017

New Online Resource Aims to Educate and Assist IPF Patients and Caregivers

Idiopathic Pulmonary Fibrosis, News

ProPatient has partnered with the Academy for Continued Healthcare Learning (ACHL) and the Pulmonary Fibrosis Foundation (PFF) to develop a new online resource for people affected by idiopathic pulmonary fibrosis (IPF). ... Read more